Adagene Inc. develops antibody-based cancer immunotherapies as a Nasdaq-listed foreign issuer whose securities trade as ADSs under ADAG. The company uses computational biology and artificial intelligence through its proprietary Dynamic Precision Library platform, including NEObody, SAFEbody and POWERbody technologies, to design masked and engineered antibody programs.
Recurring company updates center on muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody, clinical data in microsatellite stable colorectal cancer and hepatocellular carcinoma, combination studies with checkpoint and bispecific therapies, and FDA Fast Track designation in MSS metastatic colorectal cancer. Other developments include scientific meeting presentations, SAFEbody collaborations and licensing, advisory board changes, financial results and ADS capital offerings.
Adagene Inc. (Nasdaq: ADAG) announced on October 21, 2021, that CEO Peter Luo, Ph.D., will provide a corporate update at the Jefferies Virtual China Biotech Summit on October 26, 2021, at 3:00 p.m. Eastern. The online presentation will offer investors insights into Adagene’s advancements in antibody-based immunotherapies. A live webcast will be available on the company’s website, with a replay accessible for at least 30 days. Adagene leverages AI and computational biology to develop novel immunotherapy solutions using its proprietary Dynamic Precision Library platform.
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 9-15, 2021. Peter Luo, Co-founder and CEO, will present on September 10, 2021, at 2:00 p.m. Eastern. A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days. Adagene focuses on antibody-based cancer immunotherapies, leveraging its proprietary Dynamic Precision Library platform to meet unmet patient needs.
Adagene reported significant advancements in its oncology pipeline, establishing three collaborations with Merck for global combination trials involving pembrolizumab. Their lead candidate, ADG106, displayed a 56% disease control rate in monotherapy trials. Additionally, ADG116 and ADG126 are progressing through phase 1 trials, showcasing promising safety profiles. Financially, cash reserves increased to $208.3 million, attributed to a successful IPO. However, the company faced a net loss of $37.2 million for the first half of 2021, up from $18.2 million the previous year.
Adagene Inc. announces a collaboration with Merck to evaluate its product candidate ADG106 in combination with KEYTRUDA for patients with advanced or metastatic malignancies. This third clinical trial, designated ADG106-P2001/KEYNOTE-D12, follows promising Phase I trial data. ADG106, developed using the NEObody platform, targets CD137 to activate the immune response against cancer cells. The study aims to address significant unmet medical needs for patients unresponsive to existing treatments.
Adagene Inc. (Nasdaq: ADAG) announced key appointments to its leadership team, including Steven Fischkoff as interim Chief Medical Officer and new members of its Scientific and Strategic Advisory Board. This team comprises experts with extensive backgrounds in immuno-oncology, aimed at revolutionizing cancer therapeutics. Their experience includes pivotal roles in developing major immunotherapy products. CEO Peter Luo expressed confidence that these appointments will enhance Adagene's capabilities in global clinical development and the advancement of its innovative antibody-based pipeline.
Adagene Inc. (Nasdaq: ADAG) announced a collaboration with Merck to conduct two clinical studies assessing the NEObody™ candidate, ADG116, and the SAFEbody™ candidate, ADG126, combined with KEYTRUDA® for patients with advanced solid tumors. Both studies aim to evaluate the safety and efficacy of these candidates in enhancing therapeutic outcomes while addressing historical safety concerns with CTLA-4 therapies. Preliminary data suggests favorable tolerability and promising early outcomes, marking essential progress in Adagene's clinical development program.
Adagene Inc. (Nasdaq: ADAG) announced a share repurchase program authorizing up to US$20 million in buybacks of its ordinary shares in the form of American depositary shares. This decision reflects the board's strong confidence in the company's innovative pipeline driven by proprietary platforms like NEObody, SAFEbody, and POWERbody. Share repurchases are expected to be conducted in compliance with regulatory requirements and market conditions. The program is set to last for twelve months and aims to enhance shareholder value.
Adagene Inc. (Nasdaq: ADAG) announced its inclusion in the FTSE Global Equity Index Series, effective June 21, 2021. This milestone is expected to enhance the company's visibility among investors and signifies market acceptance. Adagene focuses on developing antibody-based immunotherapies through its proprietary platforms: NEObody, SAFEbody, and POWERbody. FTSE Russell's indexes are used by global institutional investors for performance benchmarking and investment fund creation.
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced that its CEO, Peter Luo, Ph.D., will present at two upcoming conferences: the Jefferies Virtual Healthcare Conference on June 4, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. At these events, Adagene will discuss its innovative approaches in antibody-based cancer immunotherapies using its proprietary DPL platform, which includes NEObody, SAFEbody, and POWERbody technologies.
Adagene Inc. (Nasdaq: ADAG) announced positive Phase I clinical trial results for its anti-CD137 antibody, ADG106, showcasing a favorable safety profile and promising efficacy in patients with advanced solid tumors and non-Hodgkin lymphoma. Key findings include a 56% disease control rate and significant tumor shrinkage (over 30%) in 75% of biomarker-positive patients. The company plans to enhance patient stratification using the identified predictive biomarker in upcoming trials. ADG106's innovative design leverages Adagene's proprietary NEObody platform, aiming for future advancements in precision immuno-oncology.